A clinical trial involving leuprolide updated its status as of November 4, 2026. The study, titled "A Study of Shorter Course Hormone Therapy and Radiation for High-risk Prostate Cancer," is registered as NCT05100472. It is a Phase 2 trial evaluating a shorter course of hormone therapy combined with radiation in patients with high-risk prostate cancer.
The trial's current status is listed as active, not recruiting. This means the study is ongoing and participants are being treated or followed, but new participants are not currently being enrolled. No results have been reported in this update, and no efficacy or safety outcomes are described at this stage.
Leuprolide is an approved compound commonly used in hormone therapy contexts such as this trial. This update reflects only the trial's administrative status change and does not indicate any findings about how the therapy performs.
Readers interested in background on leuprolide, including its approved uses and general profile, can consult the compound overview for additional context.